Investors in BOLT have the chance to take the lead in a securities fraud lawsuit against Bolt Biotherapeutics, Inc.
BOLT investors have the chance to take the lead in a securities fraud lawsuit against Bolt Biotherapeutics, Inc.
BOLT
BOLT Stockholders are advised to reach out to the shareholder rights law firm Robbins LLP for details regarding the class action against Bolt Biotherapeutics, Inc.
Bolt Therapeutics Inc. is facing a class action lawsuit as stockholders are suing the company. Robbins LLP is reminding investors about the legal action.
Bolt Biotherapeutics Inc (BOLT) reported highlights from its Q1 2024 earnings call, which included strategic shifts.
Key updates comprise changes in leadership, a notable reduction in workforce, and positive advancements in cancer treatment trials. Stocks related to these updates include BOLT.
Q1 2024 Earnings Call Transcript for Bolt Biotherapeutics Inc.
Related stocks include NAS:BOLT.
Q1 2024 Earnings Call Transcript for Bolt Biotherapeutics Inc. Read More »
Guggenheim becomes more cautious about Bolt Biotherapeutics, lowers their rating on the stock.
Visit thefly.com for up-to-date financial news. The Fly is recognized for its market intelligence and offers a real-time news feed.
